br3409
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 5, 2024 (NCT06879132)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 1INHIBITOR
BRD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06879158 | Phase 1 | Nov 10, 2024 | Boryung Pharmaceutical Company |
| NCT06879132 | Phase 1 | Nov 5, 2024 | Boryung Pharmaceutical Company |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 1 | 2024 |
1 organizations
Page 1 / 1